AMPLIFY-TIR Study in Clinical Research: Advancing T2DM Clinical Trials in India

The AMPLIFY-TIR Study marks a significant advancement in clinical research for type 2 diabetes mellitus (T2DM clinical trial), focusing on improving glycaemic control through innovative combination therapies. Conducted across multiple centres in India, this study evaluates the effectiveness of fixed-dose combinations (FDCs) of SGLT2 inhibitors and DPP-4 inhibitors using advanced continuous glucose monitoring (CGM) technology.

What is the AMPLIFY-TIR Study in Diabetes Clinical Trial, India?

The AMPLIFY-TIR Study is designed to assess targeted anticoagulant therapies in patients requiring optimized thrombosis prevention. It builds upon earlier research in anticoagulation, focusing on balancing efficacy with reduced bleeding risks—one of the primary concerns in long-term anticoagulant use.

Overview of the T2DM Clinical Trial in AMPLIFY-TIR Clinical Study

The AMPLIFY-TIR Study is a prospective, randomized, open-label, triple-arm clinical trial designed to assess glycaemic outcomes in Indian patients with T2DM who are on stable metformin therapy.

Key Study Highlights: T2DM clinical Study

• Participants: 90 adult patients with T2DM
• Study Design: Randomized, open-label, multi-centre
• Locations: 6 clinical research sites across India
• Treatment Arms:
  • Teneligliptin + Dapagliflozin
  • Sitagliptin + Dapagliflozin
  • Linagliptin + Empagliflozin
• Technology Used: Continuous Glucose Monitoring (CGM)

Study Objectives Of Diabetes Clinical Trial in AMPLIFY-TIR

The primary goal of Diabetes Clinical Trial in AMPLIFY-TIR diabetes clinical study is to evaluate the clinical utility of SGLT2i + DPP-4i combinations in improving glycaemic parameters.

Key Objectives Include:

• Improving glycaemic stability and control
• Reducing glycaemic variability
• Increasing time in range (TIR) using CGM
• Assessing safety and tolerability of combination therapies

Key Outcomes & Findings Of AMPLIFY-TIR Clinical Research

The AMPLIFY-TIR clinical evaluatiion demonstrated promising results in managing T2DM:

• Significant improvement in glycaemic stability
• Reduction in glucose fluctuations measured via CGM
• Enhanced Time in Range (TIR) outcomes
• Favourable safety profile with no new safety concerns

These findings reinforce the growing importance of combination therapies in modern diabetes management.

Importance of AMPLIFY-TIR in Clinical Investigation

The study contributes to the evolving landscape of diabetes care by:

• Supporting evidence-based treatment strategies
• Promoting personalized medicine approaches
• Demonstrating the value of real-time glucose monitoring
• Enhancing treatment adherence and patient outcomes

Role of CliniExperts Research in the AMPLIFY-TIR Study

CliniExperts Research played a pivotal role as the Contract Research Organization (CRO) for the Indian arm of the AMPLIFY-TIR study, ensuring seamless execution and regulatory compliance.

Key Contributions Of Cliniexperts Research in Diabetes Clinical Trial India

Clinical Trial Management

• End-to-end management of study operations across multiple sites
• Coordination between investigators, sponsors, and stakeholders

Site Management & Monitoring

• Selection and activation of clinical trial sites
• Regular monitoring to ensure protocol adherence and data integrity

Regulatory & Ethics Compliance

• Managing approvals from regulatory authorities and ethics committees
• Ensuring adherence to ICH-GCP guidelines and local regulations

Data Collection & Quality Assurance

• Implementation of robust data management systems
• Ensuring accurate and high-quality clinical data

Patient Recruitment & Retention

• Supporting enrolment strategies
• Enhancing patient engagement and compliance

CGM-Based Study Execution

• Facilitating integration of continuous glucose monitoring (CGM) technology
• Ensuring accurate tracking of glycaemic parameters like TIR

Through its expertise, CliniExperts Research contributed significantly to the successful completion and reliability of the AMPLIFY-TIR Clinical Research.

Recent News & Updates on AMPLIFY Studies (2025–2026)

New “AMPLIFY” Phase III Study (Different Indication – Oncology Imaging)

Recent news highlights a new Phase III AMPLIFY study (not anticoagulation-focused) involving prostate cancer imaging:

• A registrational Phase III AMPLIFY trial using 64Cu-SAR-bisPSMA PET imaging has:
  • Successfully reached its target patient enrollment (~220 participants)
  • Been conducted across the US and Australia
  • Aimed to improve detection of recurrent prostate cancer
• The study is expected to support FDA approval of a new diagnostic imaging agent

Key Insight:
The “AMPLIFY” name is now being used across multiple therapeutic areas, not just thrombosis—showing how successful trial branding often expands into new pipelines.

No Major “AMPLIFY-TIR” Breaking News (as of 2026)

• There is no recent major headline or press release specifically for “AMPLIFY-TIR”
• Most available updates relate to:
  • The original AMPLIFY anticoagulation trial
  • Post-hoc analyses and real-world data
  • Expansion of the AMPLIFY framework into other studies

This suggests that AMPLIFY-TIR may currently be:

• A sub-analysis / extension concept (Time in Therapeutic Range – TTR focused)
• Or not a standalone branded trial in recent publications/news cycles

Latest Clinical Insights from AMPLIFY Data (Still Relevant Today)

Even without fresh news, AMPLIFY-derived insights continue to shape research:

• The original AMPLIFY trial showed:
  • Apixaban is non-inferior to conventional therapy for VTE prevention
  • Significantly lower bleeding risk (≈69% reduction)
• Early-phase analysis confirms:
  • Lower recurrence and bleeding even in first weeks of treatment
• Warfarin management challenges (relevant to TIR concepts):
  • Average Time in Therapeutic Range (TTR) ~60.9% in AMPLIFY

Why this matters for AMPLIFY-TIR:
TIR-focused analyses are crucial because they:

• Highlight limitations of warfarin therapy
• Justify shift toward DOACs (e.g., apixaban)
• Support personalized anticoagulation strategies

Conclusion

The AMPLIFY-TIR Study represents a major step forward in T2DM clinical research in India, highlighting the effectiveness of SGLT2 and DPP-4 inhibitor combinations. With strong clinical outcomes and advanced CGM insights, the study paves the way for improved diabetes management strategies.

Backed by the operational excellence of CliniExperts Research, the study stands as a benchmark for high-quality, patient-centric clinical trials in India.